Application of wedelolactone in preparing drug for treating idiopathic pulmonary fibrosis
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of wedelolide and pulmonary fibrosis, which is applied in the field of biomedicine and can solve the problems of lack of IPF relief and treatment
Inactive Publication Date: 2018-12-11
MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
View PDF1 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
In October 2014, the FDA approved pirfenidone as the world's first drug for the treatment of idiopa
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0044] Example 1 Wedelolide inhibits TGF-β1-induced lung epithelial cell transformation (EMT) process and fibroblast to myofibroblast transdifferentiation process, cell migration, and TGF-β1-induced Smad and non- Smad signaling pathway
[0047] 1.2 Experimental cells: Human lung cancer epithelial cells A549, MRC-5 human embryonic lung fibroblasts (Cell Center, School of Basic Science, Chinese Academy of Medical Sciences)
[0048] 1.3 Experimental reagents and consumables: DMEM medium, MEM medium, FBS and PenStrep (Gbico company)
[0049] 2. Experimental method
[0050] 2.1 The effect of wedelolide pretreatment on TGF-β1-induced A549 cells and MRC-5 cells characteristic proteins
[0051] Select logarithmic phase A549 cells and MRC-5 cells, take 3mL (2×10 5 cells / mL) were seeded in a 6 cm diameter cell culture dish. 37°C, 5% CO 2 After cul...
Embodiment 2
[0082] The treatment of embodiment 2 wedelolide to bleomycin-induced idiopathic pulmonary fibrosis (IPF) model mice
[0083] 1. Establishment of bleomycin-induced IPF model mouse model
[0084] Take SPF grade C57BL / 6 mice (18-20g / only), anesthetize the mice with 10% pentobarbital sodium intraperitoneal injection, put the mice in the ultra-clean workbench, fix the head and limbs, and disinfect with alcohol cotton Neck skin. Make an incision as small as possible in the middle of the neck, separate the tissues layer by layer with blunt surgical instruments, expose the trachea, inject bleomycin (3U / kg) into the trachea with a micro-injector, and immediately put the mouse upright and place it in place. Rotate to make the liquid evenly distributed in the lungs, and the control group was injected with equal volume of normal saline into the trachea.
[0085] 2. Grouping and administration
[0086] All animals were randomly divided into 4 groups, 40 in each group: (1) normal control...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to an application of wedelolactone in preparing a drug for treating idiopathic pulmonary fibrosis. By taking a mode of converting a TGF-beta1 induced human pulmonary epithelial cell A549 into a mesenchymal cell and a mode of differentiating a human embryonic lung fibroblast MRC-5 to myofibroblast as research objects, wedelolactone plays roles of inhibiting conversion of the TGF-beta1 induced human pulmonary epithelial cell A549 into the mesenchymal cell and differentiation of the human embryonic lung fibroblast MRC-5 to myofibroblast by inhibiting TGF-beta1 induced Smad and non-Smad signal channels. The wedelolactone improves the respiratory function and the survival rate of a mouse by improving pulmonary fibrosis related pathological change, reducing deposition of extracellular matrix proteins (ECM), adjusting expression of key proteins of the Smad signal channel and inhibiting accumulation of inflammatory cells, thereby playing a treatment role of inhibiting a pulmonary fibrosis pathological process induced by bleomycin.
Description
technical field [0001] The invention relates to the field of biomedicine, in particular to the application of wedelolide in the preparation of medicines for treating idiopathic pulmonary fibrosis. Background technique [0002] Idiopathic pulmonary fibrosis (IPF) is a special type of chronic progressive fibrotic interstitial pneumonia of unknown cause. The disease mostly occurs in elderly patients, and the lesions are limited to the lungs. Histopathology and high-resolution CT examinations often show the characteristics of ordinary interstitial pneumonia. Worldwide, the incidence of IPF is about 2-29 cases per 100,000 people, and there is an increasing trend year by year. The clinical prognosis of IPF is poor, and the average survival time of patients after diagnosis is 3-5 years. In October 2014, the FDA approved pirfenidone as the world's first drug for the treatment of idiopathic pulmonary fibrosis. Previously, there was no effective drug for the alleviation and treatmen...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more
IPC IPC(8): A61K31/37A61P11/00
CPCA61K31/37
Inventor 杨信怡游雪甫董文婷王秀坤李聪然卢曦庞晶胡辛欣聂彤颖李国庆李雪
Owner MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Login to view more 
Login to view more